dehydroepiandrosterone

(redirected from Prasterone)
Also found in: Medical, Encyclopedia.

de·hy·dro·ep·i·an·dros·te·rone

 (dē′hī-drō-ĕp′ē-ăn-drŏs′tə-rōn′)
n.
DHEA.

dehydroepiandrosterone

(diːˌhaɪdrəʊˌɛpɪænˈdrɒstəˌrəʊn)
n
(Biochemistry) the most abundant steroid in the human body, that is involved in the manufacture of testosterone, oestrogen, progesterone, and corticosterone
Translations

dehydroepiandrosterone (DHEA)

n dehidroepiandrosterona (DHEA)
Mentioned in ?
References in periodicals archive ?
com)-- The European Commission has adopted the following on 8 January 2018: Adoption of Commission Implementing Decision granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for "Intrarosa - Prasterone," a medicinal product for human use.
acolbifene hydrochloride + prasterone + GnRH agonist - Drug Profile 81
Prasterone (Intrarosa), a once-daily intra-vaginal dehydroepiandrosterone (DHEA) product, is a prohormone that increases local estrogen and testosterone and has the advantage of improved sexual function, desire, arousal, lubrication, orgasm, satisfaction, as well as pain at sexual activity.
According to the company, Intrarosa contains prasterone, an inactive endogenous steroid, which is converted locally in the vagina into androgens and estrogens to help restore the vaginal tissue, improvements in the percentage of superficial cells, parabasal cells, pH as well as pain with intercourse.
Intrarosa is the first FDA product containing the active ingredient prasterone, which is also known as dehydroepiandrosterone (DHEA).
Intrarosa is the first FDA approved product containing the active ingredient prasterone, which is also known as dehydroepiandrosterone (DHEA).
In addition, prasterone (Prestara), a synthetic form of dehydroepiandrosterone (DHEA), is being studied as a treatment for steroid-induced osteoporosis in women with lupus, and the drug LJP 394 (Riquent) may be able to block some of the antibodies that are believed to promote kidney disease in people with the disease.
Effects of oral prasterone (dehydroepiandrosterone) on single-dose pharmacokinetics of oral prednisone and cortisol suppression in normal women.
Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy.
A medication combining the drug prasterone and the hormone dehydroepiandrosterone, or DHEA, stabilizes or improves symptoms of the autoimmune disease lupus, according to a study from a company in California.
According to the companies, Intrarosa is the only US FDA-approved, locally administered, daily, non-estrogen product and contains prasterone, a precursor of hormones that is converted locally inside the vaginal cells into androgens and estrogens with no meaningful increases detected in the blood.
7% in the lumbar spine and 2% in the hip among 24 women with lupus who took the adrenal androgen prasterone (also known as dehydroepiandrosterone or DHEA), compared with 31 women who received placebo.